Karyopharm Therapeutics

Karyopharm Therapeutics Inc., a pharmaceutical company based in Newton, Massachusetts, specializes in the discovery, development, and commercialization of drugs targeting nuclear transport and related pathways for cancer treatment. Its lead product, XPOVIO (selinexor), is an approved therapy for multiple myeloma, both as a standalone treatment and in combination with other drugs. The company's pipeline includes several clinical-stage compounds, such as BOSTON, STORM, STOMP, and SADAL, which are being evaluated in various blood cancers. Additionally, Karyopharm has collaborations with other organizations for COVID-19 and neurological disease research.